Objective: Postmenopausal hormone therapy (HT), which consists of exogenous estrogens with or without combined progestogens, remains the most effective treatment of climacteric symptoms. Depending on its characteristics, it may nevertheless increase the risk of venous thromboembolism, and its effects on hemostasis have been studied for several decades. The aim of this review was to summarize current knowledge on the effects of HT on hemostasis, taking into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens.
W omen are subject to steroid sex hormone exposure from puberty to menopause and at other times if prescribed postmenopausal hormone therapy (HT). HT remains the most effective treatment of climacteric symptoms 1 but may increase the risk of venous thromboembolism (VTE). 2, 3 Nevertheless, there is now compelling evidence that thrombotic effects of HT may strongly depend on the route of estrogen administration, 4<9 the daily dose 8 and chemical structure 10, 11 of estrogens, and the pharmacologic class of progestogens. 5, 7, 9 The effects of HT on hemostasis have been studied for several decades with dual interest. On one hand, investigating coagulation balance or imbalance among HT users provides biological support for the thrombogenic potential of specific treatments. 12<15 On the other hand, some hemostatic variables have been validated as surrogate markers of VTE 16<18 and can be used to investigate the pharmacologic effects of HT on thrombosis. 19 During the early 1980s, factors and inhibitors of coagulation and fibrinolysis were the only hemostatic variables that have been investigated in response to HT use. A few years later, activation markers have been found to be helpful as markers of coagulation and/or fibrinolysis. More recently, some global assays used to test hypercoagulability state have been validated as surrogate markers of VTE risk.
Based exclusively on data from randomized trials that included a control arm (either placebo or no treatment), this review summarizes the results of studies on HT and hemostasis, taking into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens. 12,13,20<49 HEMOSTASIS AND THROMBOSIS BIOMARKERS Hemostasis is a physiological state that includes both coagulation and fibrinolysis (Fig. 1 ). The hemostatic system, together with platelets, maintains blood in fluid state under normal conditions and can activate controlled mechanisms to prevent blood loss. 50, 51 Coagulation cascade is a set of initiation and amplification processes that lead, in its final phase, to fibrin clot after the conversion of fibrinogen by thrombin, the key enzyme of the system. After activation of several coagulation factors, both intrinsic and extrinsic pathways lead to activated factor X, which is responsible (together with activated factor V) for thrombin generation after proteolytical cleavage of prothrombin and release of prothrombin fragment 1 + 2. Accretion of fibrin depends on both activity of the coagulation cascade and fibrinolysis, which causes degradation of fibrin. Plasminogen, the central protein of the fibrinolytic system, is converted into plasmin, which cleaves fibrin clot into D-dimers (soluble degradation products). 52<54 For decades, several generations of biomarkers have been used to investigate the thrombotic process (Table 1) . During the early years, factors and inhibitors of both coagulation and fibrinolysis were investigated, without a clear direct relationship with activation of coagulation and fibrinolysis nor with clinical risk of VTE. 4, 55 Specific activation markers of coagulation and fibrinolysis were identified and used to highlight the initiation of a physiological process that conducts to fibrin clot formation and degradation. Nevertheless, this second generation of biomarkers has not been consistently related to VTE risk. 19 More recently, global tests of hypercoagulability state have been validated as surrogate markers of VTE 16<18 and can be used both for investigating the pharmacologic effects of HT and as a plausible biological reason for the potential thrombogenic role of HT. This global test of thrombin generation is an in vitro assay of the ability of a plasma sample to generate thrombin after coagulation activation. This thrombin generation therefore reflects all integrated procoagulant and anticoagulant reactions that can be implicated and can regulate the formation and inhibition of thrombin. 56 
CHARACTERISTICS OF HT
HT was introduced in the early 1950s to counteract climacteric symptoms, including hot flushes, vaginal dryness, and depression. It was also effective in preventing osteoporosis. HT initially consisted of an estrogen compound administered alone; however, in the 1970s, progestogens were added to estrogens to reduce the increased risks of endometrial hyperplasia and cancer associated with estrogen therapy (ET). 57 To date, there are several types of HT that differ according to chemical structure, daily dose, and route of administration. The characteristics of the main marketed HT are summarized in Figure 2 .
The estrogen compound of ET consists of either 17Aestradiol (the bioidentical compound) or synthetic compounds, including estradiol valerate and conjugated equine estrogens (CEE). Natural 17A-estradiol can be administered orally and nonorally. Nonoral 17A-estradiol can be given transdermally but rarely nasally. 4, 58 Estradiol valerate is a synthetic compound administered orally; its composition and, therefore, effects are very close to those of 17A-estradiol. 59, 60 Finally, CEE are synthesized from the urine of gravid mares and contain more than 10 known biologically active estrogen compounds, including mainly estrone sulfate and equilin sulfate. CEE are always orally administered. 10 Progestogen compounds of estrogen-progestogen therapy (EPT) include both progesterone (the bioidentical compound synthesized and secreted by the ovary) and synthetic compounds named progestins, which are derived from either progesterone (pregnanes and 19-norpregnanes) or testosterone (19-nortestosterone) . Pregnane derivatives consist of different molecules, including dydrogesterone, medrogestone, chlormadinone acetate, cyproterone acetate, and medroxyprogesterone acetate (MPA). Norpregnane derivatives include nomegestrol acetate, promegestone, trimegestone, and nestorone. Finally, nortestosterone derivatives consist of ethinylated derivatives, nonethinylated derivatives, spironolactone derivatives, and tibolone. Nortestosterone ethinylated derivatives are composed of estranes (including especially norethisterone acetate) and gonanes, which are preferentially used in contraceptive pills. Nortestosterone nonethinylated derivative (dienogest) and spironolactone derivative (drospirenone) are also used in contraception. As an EPT compound, progestogens are always combined with estrogens and are almost exclusively administered by the oral route. 57 Across countries, medical practices regarding HT use may present important differences in terms of chemical structure and route of administration. In France, women are preferentially prescribed transdermally administered 17A-estradiol combined with micronized progesterone. By contrast, oral CEE combined with MPA are often used in the United States.
ESTROGENS-INDUCED CHANGES IN HEMOSTASIS
HT consisting of exogenous estrogens with or without combined progestogens has long been believed to have little effect on VTE risk. However, for several decades, it has been known to induce changes in hemostasis. Nevertheless, these modifications in coagulation and fibrinolysis may depend on several HT characteristics, including especially the route of estrogen administration (Table 2) . Route of estrogen administration Among the 28 selected randomized controlled trials of HT and hemostasis that included a control group (either placebo or no treatment), a large majority investigated only the effects of oral estrogens. 20<24,26<32,34<36, 39, 42, 43, 45, 46, 48, 49 Some of them included both oral and transdermal arms, 12, 13, 37, 38, 44 and only five trials had a transdermalVbut not an oralV group. 25, 33, 40, 41, 47 
Oral estrogens
Overall, there is no clear effect of oral estrogens on coagulation factors, including fibrinogen, factor VII, factor VIII, thrombin, and prothrombin. Until the end of the 1990s, all studiesVexcept for one 22 Vfound no change in these parameters among oral estrogen users compared with nonusers or placebo users. 12, 20, 23, 27 Since 2001, several studies have shown that some of these parameters, especially fibrinogen, factor VII, and factor VIII, decreased in oral groups without a clear biological explanation for such reduction. 28,29,31,34,37<39,43,45,46 This time-dependent discrepancy between early and recent studies may in part be explained by a lack of standardization in laboratory methods, which leads to important differences in biological assays. With respect to inhibitors of coagulation, most of the studies reported a significant decrease in antithrombin and/or protein C and protein S among users of oral estrogens, suggesting a hemostatic imbalance caused by these treatments. 12,13,21,27,29,31,35,37<39,43 Evidence for an effect of oral estrogens on fibrinolysis factors emerged neither for plasminogen nor for tissue plasminogen activator, with various studies showing no change, an increase, or a decrease in one or both factors. 12,20,23,27,29,32,35<38,45,46 By contrast, plasminogen activator inhibitor 1 (as a fibrinolysis inhibitor) has been consistently found to decrease with the use of oral estrogens that may thus promote a fibrinolytic process in response to initial coagulation activation. 12,26,27,29,32,35<39,45,46 Overall, these results on factors and inhibitors of coagulation and fibrinolysis in users of oral estrogens are consistent with studies that found, on the whole, an increase in activation markers of coagulation and therefore Bin-response[ fibrinolysis, as shown by changes in prothrombin fragment 1 + 2 and D-dimer concentrations. 12, 13, 21, 26, 27, 31, 35, 37, 38 Since 2001, several studies have used hemostatic global tests, including baseline thrombin generation and thrombin generation with or without activated protein C (APC), to evaluate the effects of HT on hypercoagulability state. 13,28<30,34,37,38,43,48,49 Most of the studies found an important and significant increase in APC resistance or baseline thrombin generation associated with oral estrogen use. 13, 30, 34, 37, 38, 48, 49 Nevertheless, the biological mechanism for such APC resistance in postmenopausal women using oral estrogens remains largely not understood. Some studies have found that changes in protein S and tissue factor pathway inhibitor levels might have important roles in determining APC resistance in women receiving oral estrogens. 15, 61 Others reported that the soluble form of endothelial protein C receptor, which has been reported to inhibit APC anticoagulant activity, might therefore be a candidate for explaining APC resistance. 62 The three studies that showed no APC resistance with oral estrogens 28, 29, 43 used a biological method that has been demonstrated to be sensitive to factor V Leiden mutation but not to exogenous estrogens. 13 It is important to remark that these results concern estrogens alone or estrogens administered in combination with a progestogen. Because women prescribed ET had been hysterectomized and account for less than 20% of hormone therapy users in industrialized countries, only some studies included an unopposed arm to evidence the main effects of estrogens, irrespective of progestogens. 21,27,29,32,34,37,38,44<46 Nevertheless, analysis restricted to ET led to similar results.
Taken together, these results show that oral estrogens cause a hemostatic imbalance that leads to blood coagulation activation and hypercoagulability state. This biological process is consistent with clinical studies that found an increased thrombotic risk among users of oral estrogens. 63 
Transdermal estrogens
The effects of transdermal estrogen use on hemostasis were assessed for the first time in a randomized controlled trial in 1997. 12 Results regarding coagulation factors have been inconsistent, with some studies showing no change in transdermal estrogen users 12, 25, 33, 47 and with others finding decreased levels of fibrinogen, 41 factor VII, 38, 41 or factor VIII. 38, 40, 41 Similarly, although inhibitors of coagulation have been found to decrease in four randomized controlled trials, 13, 25, 37, 41 other investigations found no changes. 12, 47 Results regarding factors and inhibitors of fibrinolysis were more coherent; all studies, except for one, 41 found no change in these parameters between users of transdermal estrogens and nonusers or placebo users. 12, 25, 33, 37, 40, 47 In the same way, most of the studies showed no effect of transdermal estrogens on markers of coagulation and fibrinolysis 12, 13, 25, 33, 38, 40 ; this maintenance of hemostasis balance was confirmed in studies by Oger et al 13 and Post et al, 37 who both found no APC resistance in transdermal estrogen users compared with placebo users.
Altogether, the results consistently showed that transdermal estrogens have little or no effect on hemostasis. Furthermore, in this case, this biological effect is consistent with the results of clinical studies that found a similar thrombotic risk between users of transdermal estrogens and HT nonusers. 63 
Oral versus transdermal estrogens
Only three studies included together oral estrogen and transdermal estrogen arms to directly compare the effects of route of administration. 12, 13, 37, 38 In the IMEP (Ifosfamide, Methotrexate, Etoposide, and Prednisolone) trial, Scarabin et al 12 reported a significant increase in prothrombin fragment 1 + 2 with oral estrogen use compared with transdermal estrogen use. A few years later, Oger et al 13 confirmed this result in the SARAH (Strengthening And stretching for Rheumatoid Arthritis of the Hand) trial. In addition, this latest study, 13 taken together with the investigation by Post et al, 37 showed that the increase in APC resistance with oral estrogen use was significant compared with transdermal estrogen use. Biological and clinical results are once again consistent. 63 
Chemical structures
Oral 17A-estradiol and oral CEE were included together and compared only in one randomized controlled trial, but statistical analysis did not allow comparison of their respective effects on hemostasis. 42 Nevertheless, an indirect comparison of several other selected studies suggests no difference in HT effects on hemostasis between 17A-estradiol, estradiol valerate, and CEE. Because transdermal administration exclusively concerns 17A-estradiol, no potential effect of chemical structure can be assessed for transdermal estrogens.
Daily dose
Studies of different doses of the same estrogen compound are scarce and only concern the oral route of administration. 21, 23, 32, 48 In their study, Caine et al 21 found a dose effect of oral estrogens that remained borderline for prothrombin fragment 1 + 2 and fibrinopeptide A but reached significance for antithrombin, protein S, and protein C. A few years later, Conard et al 23 found no effect of oral estrogens at any daily dose, and Lobo et al, 32 who investigated three doses of CEE with or without MPA, did not highlight a significant dose effect of oral estrogens on hemostasis. Recently, Rousseau et al 48 found no significant difference between two daily doses of oral 17A-estradiol.
Overall, there is no clear evidence for a significant dose effect of oral estrogens on hemostatic variables.
EFFECT OF PROGESTOGENS ON HEMOSTASIS
Progestogens consisting of several compounds with different pharmacologic properties 64 are systematically added to estrogens for women with an intact uterus to reduce the increased risks of endometrial hyperplasia and cancer associated with ET. 57 
Chemical structures
Randomized controlled trials that are able to assess the main effects of a progestogen or to compare different progestogens are scarce and only concern progestogens combined with oral estrogens. 22, 27, 32, 34, 37, 38 In the PEPI (Postmenopausal Estrogen/Progestin Interventions) trial, MPA was administered either sequentially or continuously, and these two hormone regimens were compared with micronized progesterone or no progestogen. 22 Results showed similar changes in fibrinogen across different active groups, with neither an effect of addition of a progestogen nor a specific effect of different chemical structures. 22 A few years later, Lobo et al 32 conducted a large trial with different doses of CEE alone or combined with MPA and did not highlight any evidence for a specific effect of MPA on hemostatic parameters. At the same time, van Baal et al 27 and Post et al 34 investigated the impact of dydrogesterone and trimegestone, a pregnane and a norpregnane derivative, respectively. Here, they also found no difference in their effects on hemostasis and pooled the two groups receiving opposed oral estrogens for some specific analyses. 27, 34 In another study, the main effect of gestodene, a testosterone derivative, was assessed by comparing changes in hemostatic parameters between two arms consisting of oral estrogens either alone or combined with this progestin. 37, 38 This was the only study that found a decrease in protein C in the opposed oral estrogens group but not in the estrogens-alone group. 37, 38 Overall, randomized controlled trials did not consistently detect any specific effect of progestogen on hemostasis among postmenopausal women using oral estrogens. Nevertheless, this absence of association does not necessarily imply that progestogens have no effect. It could be partly explained by a lack of statistical power and/or a dilution effect caused by the concomitant use of oral estrogens that activate blood coagulation by themselves and might then hide the specific effect of progestogens. A cross-sectional study on postmenopausal EPT and hemostasis suggested that norpregnane derivatives and micronized progesterone could have a differential effect on APC resistance and blood coagulation activation when combined with transdermal estrogens. 15 In addition, clinical data support a differential effect of pharmacologic classes of progestogens on thrombotic risk. 5, 7 Further data on the biological and clinical effects of progestogens are therefore needed, especially in the context of transdermal estrogen use.
Daily dose
Only two randomized controlled trials assessed the differential effects of two progestogen doses, and both concerned oral estrogen use. 23, 32 On one hand, Conard et al 23 found no difference in progestogen effect on hemostasis between two doses of nomegestrol acetate but did not find any effect of oral estrogens. One can therefore wonder about the compliance of the participants and/or the validity of biological assays. On the other hand, use of opposed CEE led to similar 13-month changes in hemostasis irrespective of the dose of combined MPA. 32 
CONCLUSIONS
This review is a summary of randomized controlled trials that included a control group and investigated the effects of HT on hemostasis. This comprehensive analysis takes into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens. There is compelling evidence for a differential effect of estrogens according to route of administration, with blood coagulation activation and hypercoagulability state among oral estrogen users and definite hemostatic balance among transdermal estrogen users. This difference depends on neither the estrogen compound nor the daily dose. Clinical results showing an increased VTE risk among oralV but not transdermalVestrogen users are absolutely consistent with these biological results. By contrast, although some clinical studies have suggested that progestogens could be another important determinant of thrombotic risk, no clear effect of the different progestogens on hemostasis has been highlighted.
